These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35201622)

  • 61. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Role of
    Pilarski R
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():79-86. PubMed ID: 31099688
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Germline and Somatic Mutations in Prostate Cancer for the Clinician.
    Cheng HH; Sokolova AO; Schaeffer EM; Small EJ; Higano CS
    J Natl Compr Canc Netw; 2019 May; 17(5):515-521. PubMed ID: 31085765
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Positive Impact of Implementing a Comprehensive Genetic Testing Protocol for Prostate Cancer Patients in a Multi-disciplinary Uro-oncology Practice.
    Ramanathan S; Korman A; Ramanathan S; Korman H; Ghilezan MI; Levin M; Wojno K; Martinez A; Balaraman S
    Urol Pract; 2023 Jan; 10(1):34-39. PubMed ID: 37103436
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Genetics of prostate cancer and its utility in treatment and screening.
    Benafif S; Ni Raghallaigh H; McHugh J; Eeles R
    Adv Genet; 2021; 108():147-199. PubMed ID: 34844712
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genetic predisposition to prostate cancer: an update.
    Ni Raghallaigh H; Eeles R
    Fam Cancer; 2022 Jan; 21(1):101-114. PubMed ID: 33486571
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology.
    Amini AE; Salari K
    JCO Precis Oncol; 2024 Feb; 8():e2300560. PubMed ID: 38412389
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
    Carlo MI; Giri VN; Paller CJ; Abida W; Alumkal JJ; Beer TM; Beltran H; George DJ; Heath EI; Higano CS; McKay RR; Morgans AK; Patnaik A; Ryan CJ; Schaeffer EM; Stadler WM; Taplin ME; Kauff ND; Vinson J; Antonarakis ES; Cheng HH
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30761386
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Motivation and family communication in hereditary prostate cancer genetic testing: Survey of patients from a US tertiary medical center.
    Finn CM; McCormick S; Peterson D; Niendorf KB; Rodgers LH
    J Genet Couns; 2023 Feb; 32(1):79-89. PubMed ID: 35941805
    [TBL] [Abstract][Full Text] [Related]  

  • 70. MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
    Rayes N; Bowen DJ; Coffin T; Nebgen D; Peterson C; Munsell MF; Gavin K; Lechner R; Crase J; Polinsky D; Romero I; Blank SV; Levine DA; Norquist BM; Swisher EM; Lu KH
    BMC Cancer; 2019 Jul; 19(1):648. PubMed ID: 31266460
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Genetic profiling in the diagnosis of hereditary prostate cancer: Where do we stand?].
    Boehm K; Thomas C; Tsaur I
    Aktuelle Urol; 2018 Dec; 49(6):525-529. PubMed ID: 30522164
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features.
    Alberti C
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):31-41. PubMed ID: 20184087
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identifying hereditary cancer: genetic counseling and cancer risk assessment.
    Lewis KM
    Curr Probl Cancer; 2014; 38(6):216-25. PubMed ID: 25432528
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Considerations of germline testing in prostate cancer screening.
    Polascik TJ; Orabi H
    Can J Urol; 2019 Oct; 26(5 Suppl 2):46-47. PubMed ID: 31629431
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Delivering Genetic Testing for Patients with Prostate Cancer: Moving Beyond Provider Knowledge as a Barrier to Care.
    Gunn CM; Li EX; Gignac GA; Pankowska M; Loo S; Zayhowski K; Wang C
    Cancer Control; 2023; 30():10732748221143884. PubMed ID: 36946278
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Genetic testing by cancer site: stomach.
    Chun N; Ford JM
    Cancer J; 2012; 18(4):355-63. PubMed ID: 22846738
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The beliefs, and reported and intended behaviors of unaffected men in response to their family history of prostate cancer.
    Cowan R; Meiser B; Giles GG; Lindeman GJ; Gaff CL
    Genet Med; 2008 Jun; 10(6):430-8. PubMed ID: 18496220
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision Management.
    Giri VN; Hyatt C; Gomella LG
    J Clin Oncol; 2019 Jun; 37(17):1455-1459. PubMed ID: 30978156
    [No Abstract]   [Full Text] [Related]  

  • 80. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
    Walker EJ; Carnevale J; Pedley C; Blanco A; Chan S; Collisson EA; Tempero MA; Ko AH
    Fam Cancer; 2019 Apr; 18(2):241-251. PubMed ID: 30267352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.